Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C12H16N2O |
| Molecular Weight | 204.2682 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)CCC1=CNC2=C1C=C(O)C=C2
InChI
InChIKey=VTTONGPRPXSUTJ-UHFFFAOYSA-N
InChI=1S/C12H16N2O/c1-14(2)6-5-9-8-13-12-4-3-10(15)7-11(9)12/h3-4,7-8,13,15H,5-6H2,1-2H3
| Molecular Formula | C12H16N2O |
| Molecular Weight | 204.2682 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: Q64264 Gene ID: 15550.0 Gene Symbol: Htr1a Target Organism: Mus musculus (Mouse) |
|||
Target ID: P35363 Gene ID: 15558.0 Gene Symbol: Htr2a Target Organism: Mus musculus (Mouse) |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| A test of the transmethylation hypothesis in acute schizophrenic patients. | 1975 Oct |
|
| Molecular cloning of a mammalian serotonin receptor that activates adenylate cyclase. | 1993 Aug |
|
| Mouse 5-hydroxytryptamine5A and 5-hydroxytryptamine5B receptors define a new family of serotonin receptors: cloning, functional expression, and chromosomal localization. | 1993 Mar |
|
| Expression of functional mouse 5-HT5A serotonin receptor in the methylotrophic yeast Pichia pastoris: pharmacological characterization and localization. | 1995 Dec 27 |
|
| Bufotenine reconsidered as a diagnostic indicator of psychiatric disorders. | 1995 Nov 27 |
|
| Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan. | 1996 Dec |
|
| Mapping the binding site pocket of the serotonin 5-Hydroxytryptamine2A receptor. Ser3.36(159) provides a second interaction site for the protonated amine of serotonin but not of lysergic acid diethylamide or bufotenin. | 1996 Jun 21 |
|
| Functional and radioligand binding characterization of rat 5-HT6 receptors stably expressed in HEK293 cells. | 1997 Apr-May |
|
| Altered consciousness states and endogenous psychoses: a common molecular pathway? | 1997 Dec 19 |
|
| Ayahoasca: an experimental psychosis that mirrors the transmethylation hypothesis of schizophrenia. | 1999 Apr |
|
| Determination of potentially hallucinogenic N-dimethylated indoleamines in human urine by HPLC/ESI-MS-MS. | 2001 |
|
| The chemistry of indoles. CIII. Simple syntheses of serotonin, N-methylserotonin, bufotenine, 5-methoxy-N-methyltryptamine, bufobutanoic acid, N-(indol-3-yl)methyl-5-methoxy-N-methyltryptamine, and lespedamine based on 1-hydroxyindole chemistry. | 2001 Jan |
|
| Pharmañopo-psychonautics: human intranasal, sublingual, intrarectal, pulmonary and oral pharmacology of bufotenine. | 2001 Jul-Sep |
|
| Aphrodisiacs past and present: a historical review. | 2001 Oct |
|
| RNA-editing of the 5-HT(2C) receptor alters agonist-receptor-effector coupling specificity. | 2001 Sep |
|
| Aromatization of 1,6,7,7a-tetrahydro-2H-indol-2-ones by a novel process. Preparation of key-intermediate methyl 1-benzyl-5-methoxy-1H-indole-3-acetate and the syntheses of serotonin, melatonin, and bufotenin. | 2002 Apr 5 |
|
| Molecular basis of partial agonism: orientation of indoleamine ligands in the binding pocket of the human serotonin 5-HT2A receptor determines relative efficacy. | 2003 Jan |
|
| Potentially hallucinogenic 5-hydroxytryptamine receptor ligands bufotenine and dimethyltryptamine in blood and tissues. | 2005 |
|
| Occurrence of bufotenin in the Osteocephalus genus (Anura: Hylidae). | 2005 Sep 15 |
|
| Urinary excretion of dietary contaminants in horses. | 2006 Aug |
|
| New indole N-oxide alkaloids from Evodia fargesii. | 2006 Feb |
|
| Identification of 5-hydroxy-tryptamine (bufotenine) in takini (Brosimumacutifolium Huber subsp. acutifolium C.C. Berg, Moraceae), a shamanic potion used in the Guiana Plateau. | 2006 Jun 30 |
|
| [Urine peptide patterns in children with milder types of autism]. | 2006 May 25 |
|
| Lack of bufadienolides in the skin secretion of red bellied toads, Melanophryniscus spp. (Anura, Bufonidae), from Uruguay. | 2007 Jan |
|
| Liquid chromatography-tandem mass spectrometry method for the simultaneous analysis of multiple hallucinogens, chlorpheniramine, ketamine, ritalinic acid, and metabolites, in urine. | 2007 Oct |
|
| Indolealkylamines: biotransformations and potential drug-drug interactions. | 2008 Jun |
|
| Early onset muscarinic manifestations after wild mushroom ingestion. | 2008 Sep |
|
| Sudden death associated with intravenous injection of toad extract. | 2009 Jul 1 |
|
| Isolation of N,N-dimethyl and N-methylserotonin 5-O-β-glucosides from immature Zanthoxylum piperitum seeds. | 2010 |
|
| Elevated urine levels of bufotenine in patients with autistic spectrum disorders and schizophrenia. | 2010 |
|
| Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics. | 2010 Jul 1 |
|
| Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions. | 2010 Oct |
Sample Use Guides
Age-matched wild-type FVB/N and Tg-CYP2D6 mice were given an intraperitoneal dose of either harmaline 90, 2, 5, or 15 mg/kg) or bufotenine (0, 2, 10 0r 20 mg/kg). Wild-type and Tg-CYP2D6 mice exhibited hyperthermia with high doses of bufotenine ( 10 and 20 mg/kg).
Route of Administration:
Intraperitoneal
To determine if serotonin is involved in associative conditioning-produced changes of Type B photo-receptors, isolated nervous systems were exposed to a conditioning procedure in the absence or presence of drugs that alter normal serotonergic neurotransmission. Nervous systems were dissected, mounted and treated with protease before washing with artificial seawater (ASW), or ASW containing 100 microM bufotenine. When treated bufotenine clearly reduced the pairing specific cumulative depolarization and changes in input resistance. Treatment involving bufotenine suggests that serotonin modulates Type B photoreceptor excitability during associative conditioning.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 18:48:40 UTC 2023
by
admin
on
Fri Dec 15 18:48:40 UTC 2023
|
| Record UNII |
0A31347TZK
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
DEA NO. |
7433
Created by
admin on Fri Dec 15 18:48:41 UTC 2023 , Edited by admin on Fri Dec 15 18:48:41 UTC 2023
|
||
|
WIKIPEDIA |
TiHKAL
Created by
admin on Fri Dec 15 18:48:41 UTC 2023 , Edited by admin on Fri Dec 15 18:48:41 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
89593
Created by
admin on Fri Dec 15 18:48:41 UTC 2023 , Edited by admin on Fri Dec 15 18:48:41 UTC 2023
|
PRIMARY | |||
|
DB01445
Created by
admin on Fri Dec 15 18:48:41 UTC 2023 , Edited by admin on Fri Dec 15 18:48:41 UTC 2023
|
PRIMARY | |||
|
10257
Created by
admin on Fri Dec 15 18:48:41 UTC 2023 , Edited by admin on Fri Dec 15 18:48:41 UTC 2023
|
PRIMARY | |||
|
BUFOTENIN
Created by
admin on Fri Dec 15 18:48:41 UTC 2023 , Edited by admin on Fri Dec 15 18:48:41 UTC 2023
|
PRIMARY | |||
|
0A31347TZK
Created by
admin on Fri Dec 15 18:48:41 UTC 2023 , Edited by admin on Fri Dec 15 18:48:41 UTC 2023
|
PRIMARY | |||
|
DTXSID0048894
Created by
admin on Fri Dec 15 18:48:41 UTC 2023 , Edited by admin on Fri Dec 15 18:48:41 UTC 2023
|
PRIMARY | |||
|
m2753
Created by
admin on Fri Dec 15 18:48:41 UTC 2023 , Edited by admin on Fri Dec 15 18:48:41 UTC 2023
|
PRIMARY | Merck Index | ||
|
207-667-9
Created by
admin on Fri Dec 15 18:48:41 UTC 2023 , Edited by admin on Fri Dec 15 18:48:41 UTC 2023
|
PRIMARY | |||
|
3210
Created by
admin on Fri Dec 15 18:48:41 UTC 2023 , Edited by admin on Fri Dec 15 18:48:41 UTC 2023
|
PRIMARY | |||
|
487-93-4
Created by
admin on Fri Dec 15 18:48:41 UTC 2023 , Edited by admin on Fri Dec 15 18:48:41 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> AGONIST |
|
||
|
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> AGONIST |
|
||
|
|
PARENT -> ACTIVE CONSTITUENT ALWAYS PRESENT |
|
||
|
PARENT -> ACTIVE CONSTITUENT ALWAYS PRESENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE -> PARENT |
|
||
|
PARENT -> METABOLITE ACTIVE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
